CD8A and neoplasm: It is intriguing to consider that precise timing of EZH2 inhibition could potentially enlarge reservoirs of stem-like CD8+ T cells, thereby fostering larger pools of effector cells, and consequently boosting both anti-tumor and anti-viral immunity [78].